FDA : revenue, balance sheet and financial ratios

FDA is a French company founded 20 years ago, specialized in the sector Activités de centres d'appels. Based in PERIGNY (17180), this company of category PME shows in 2021 a revenue of 752 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - FDA (SIREN 485252183)
Indicator 2021 2020 2019 2018 2016
Revenue 751 561 € N/C N/C N/C 929 441 €
Net income -223 365 € -123 609 € -35 701 € -31 251 € 37 244 €
EBITDA -121 833 € N/C N/C N/C 49 513 €
Net margin -29.7% N/C N/C N/C 4.0%

Revenue and income statement

En 2021, FDA alcanza unos ingresos de 752 k€. La actividad permanece estable durante el período (TCAC: -4.2%). Tras deducir el consumo (0 €), el margen bruto se sitúa en 752 k€, es decir, una tasa del 100%. El EBITDA alcanza -122 k€, representando el -16.2% de los ingresos. Un EBITDA negativo significa que las operaciones no cubren los gastos corrientes. El resultado neto es negativo en -223 k€ (-29.7% de los ingresos).

Revenue (2021) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

751 561 €

Gross margin (2021) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

751 561 €

EBITDA (2021) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-121 833 €

EBIT (2021) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-222 303 €

Net income (2021) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-223 365 €

EBITDA margin (2021) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-16.2%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

El ratio de endeudamiento (= Deuda financiera / Fondos propios x 100) se sitúa en -0%. Este nivel muy bajo refleja una estructura financiera sólida. La autonomía financiera (= Fondos propios / Total activo x 100) alcanza el -26%. Baja autonomía: la empresa depende fuertemente de financiación externa.

Debt ratio (2021) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

-0.446%

Financial autonomy (2021) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

-25.742%

Cash flow / Revenue (2021) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

-16.284%

Repayment capacity (2021) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Asset age ratio (2021) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

70.4%

Solvency indicators evolution
FDA

Sector positioning

Ratio de endeudamiento
-0.45 2021
2019
2020
2021
Q1: 0.0
Med: 2.57
Q3: 57.44
Excelente

En 2021, el ratio de endeudamiento de FDA (-0.45) se sitúa en el 25% más bajo del sector, lo cual es positivo. Este ratio mide el peso de la deuda en relación con el patrimonio. Un ratio bajo indica una estructura financiera sólida con poca dependencia de los acreedores.

Autonomía financiera
-25.74% 2021
2019
2020
2021
Q1: 8.11%
Med: 27.74%
Q3: 45.69%
Vigilar -16 pts over 3 years

En 2021, el autonomía financiera de FDA (-25.7%) se sitúa en el 25% más bajo del sector. Este ratio representa la parte del patrimonio en la financiación total. Baja autonomía puede limitar la capacidad de inversión y aumentar la vulnerabilidad.

Capacidad de reembolso
0.0 ans 2021
2021
Q1: 0.0 ans
Med: 0.03 ans
Q3: 1.67 ans
Excelente

En 2021, el capacidad de reembolso de FDA (0.0 an) se sitúa en el 25% más bajo del sector, lo cual es positivo. Este ratio indica el número de años necesarios para pagar la deuda con flujo de caja. Una capacidad corta refleja deuda controlada y buena generación de efectivo.

Liquidity ratios

El ratio de liquidez se sitúa en 33.90. La empresa tiene 2€ de activos líquidos por cada 1€ de deuda a corto plazo.

Liquidity ratio (2021) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

33.896

Interest coverage (2021) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-0.081

Liquidity indicators evolution
FDA

Sector positioning

Ratio de liquidez
33.9 2021
2019
2020
2021
Q1: 111.11
Med: 154.78
Q3: 241.52
Vigilar -10 pts over 3 years

En 2021, el ratio de liquidez de FDA (33.90) se sitúa en el 25% más bajo del sector. Este ratio mide la capacidad de cubrir deuda a corto plazo con activos corrientes. Un ratio inferior a 1 puede señalar tensiones potenciales de flujo de caja.

Cobertura de intereses
-0.08x 2021
2021
Q1: 0.0x
Med: 0.0x
Q3: 1.52x
Average

En 2021, el cobertura de intereses de FDA (-0.1x) se sitúa por debajo de la mediana del sector. Este ratio indica cuántas veces el resultado operativo cubre los gastos de intereses. Una mejora fortalecería la posición competitiva.

Working capital requirement (WCR) and payment terms

El fondo de maniobra operativo (FM) mide el desfase temporal de tesorería. Plazo medio de cobro a clientes: 101 días. Plazo proveedores: 510 días. Excelente situación: los proveedores financian 409 días del ciclo operativo. El FM es negativo (-56 días): las operaciones generan estructuralmente tesorería. Notable mejora del FM durante el período (-166%), liberando tesorería.

Operating WCR (2021) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

-116 853 €

Customer credit (2021) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

101 j

Supplier credit (2021) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

510 j

Inventory turnover (2021) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2021) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

-56 j

WCR and payment terms evolution
FDA

Positioning of FDA in its sector

Comparison with sector Activités de centres d'appels

Valuation estimate

Based on 50 transactions of similar company sales in 2021, the value of FDA is estimated at 511 358 € (range 210 753€ - 737 536€). The price/revenue ratio is 0.68x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2021
50 tx
210k€ 511k€ 737k€
511 358 € Range: 210 753€ - 737 536€
Section année 2021 Aggregated at NAF section level

Valuation method used

Revenue Multiple
751 561 € × 0.68x = 511 359 €
Range: 210 753€ - 737 536€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 50 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Activités de centres d'appels)

Compare FDA with other companies in the same sector:

Voir toutes les statistiques du secteur Activités de centres d'appels

Frequently asked questions about FDA

What is the revenue of FDA ?

The revenue of FDA in 2021 is 752 k€.

Is FDA profitable?

FDA recorded a net loss in 2021.

Where is the headquarters of FDA ?

The headquarters of FDA is located in PERIGNY (17180), in the department Charente-Maritime.

Where to find the tax return of FDA ?

The tax return of FDA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does FDA operate?

FDA operates in the sector Activités de centres d'appels (NAF code 82.20Z). See the 'Sector positioning' section above to compare the company with its competitors.